Cancer Monoclonal Antibody Partnering Agreements

Published by: Current Partnering

Published: Nov. 1, 2012 - 583 Pages


Table of Contents

Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in cancer monoclonal antibody dealmaking
2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Bigpharma cancer monoclonal antibody dealmaking activity
2.4. Bigpharma not active in cancer monoclonal antibody partnering
2.5. Cancer vaccine partnering by deal type
2.6. Cancer monoclonal antibody partnering by stage of development
2.7. Cancer monoclonal antibody partnering by cancer indication
2.8. Cancer monoclonal antibody partnering by antibody type
2.9. Disclosed deal terms for cancer monoclonal antibody partnering
2.9.1 Cancer monoclonal antibody partnering headline values
2.9.2 Cancer monoclonal antibody deal upfront payments
2.9.3 Cancer monoclonal antibody deal milestone payments
2.9.4 Cancer monoclonal antibody royalty rates
Chapter 3 – Leading monoclonal antibody cancer deals
3.1. Introduction
3.2. Top monoclonal antibody cancer deals by value
Chapter 4 – Monoclonal antibody cancer dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By stage of development
Discovery
Formulation
Marketed
Phase I 218
Phase II
Phase III
Preclinical
4.4. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
4.5. By oncology therapy area
Bone cancer
Brain cancer
Breast cancer
Colorectal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Lung cancer
Non small cell lung cancer
Lymphoma
Hodgkin's lymphoma
Non Hodgkin's lymphoma
Melanoma
Mesothelioma
Metastases
Bone metastases
Multiple myeloma
Neuroblastoma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Non-melanoma skin cancer
Solid tumors
Thyroid cancer
4.6. By antibody type
Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb
Chapter 5 –Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendices
Appendix 1 – Deal type definitions
Appendix 2 – Example monoclonal antibody cancer partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Current Reports
Recent report titles from CurrentPartnering
Order Form – Reports
Order Form – Reports
Table of figures
Figure 1: Cancer monoclonal antibody partnering since 2007
Figure 2: Bigpharma – top 50 – cancer monoclonal antibody deals 2007 to 2012
Figure 3: Bigpharma cancer monoclonal antibody deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in cancer monoclonal antibody partnering 2007-2012
Figure 5: Cancer monoclonal antibody partnering by deal type since 2007
Figure 6: Cancer monoclonal antibody partnering by stage of development since 2007
Figure 7: Monoclonal antibody partnering by oncology target since 2007
Figure 8: Monoclonal antibody partnering by type since 2007
Figure 9: Cancer monoclonal antibody deals with a headline value – by stage of development
Figure 10: Monoclonal antibody deal headline value distribution, US$million – discovery stage
Figure 11: Monoclonal antibody deal headline value distribution, US$million – preclinical stage
Figure 12: Cancer monoclonal antibody deal headline value distribution, US$million – phase I stage
Figure 13: Cancer monoclonal antibody deal headline value distribution, US$million – phase II stage
Figure 14: Cancer monoclonal antibody deal headline value distribution, US$million – phase III stage
Figure 15: Cancer monoclonal antibody deal headline value distribution, US$million – regulatory stage
Figure 16: Cancer monoclonal antibody deal headline value distribution, US$million – marketed stage
Figure 17: Cancer monoclonal antibody deal headline value – median value by stage of development
Figure 18: Cancer monoclonal antibody deals with upfront payment values – by stage of development
Figure 19: Monoclonal antibody deal upfront distribution, US$million – discovery stage
Figure 20: Monoclonal antibody deal upfront value distribution, US$million – preclinical stage
Figure 21: Monoclonal antibody deal upfront value distribution, US$million – phase I stage
Figure 22: Monoclonal antibody deal upfront value distribution, US$million – phase II stage
Figure 23: Monoclonal antibody deal upfront value distribution, US$million – phase III stage
Figure 24: Monoclonal antibody deal upfront value distribution, US$million – regulatory stage
Figure 25: Monoclonal antibody deal upfront value distribution, US$million – marketed stage
Figure 26: Cancer monoclonal antibody deal upfront value – median value by stage of development
Figure 27: Cancer monoclonal antibody deals with milestone payment – by stage of development
Figure 28: Monoclonal antibody deal milestone distribution, US$million – discovery stage
Figure 29: Monoclonal antibody deal milestone value distribution, US$million – preclinical stage
Figure 30: Monoclonal antibody deal milestone value distribution, US$million – phase I stage
Figure 31: Monoclonal antibody deal milestone value distribution, US$million – phase II stage
Figure 32: Monoclonal antibody deal milestone value distribution, US$million – phase III stage
Figure 33: Monoclonal antibody deal milestone value distribution, US$million – regulatory stage
Figure 34: Monoclonal antibody deal milestone value distribution, US$million – marketed stage
Figure 28: Cancer monoclonal antibody deals with royalty rates
Figure 36: Monoclonal antibody deal royalty rate distribution, US$million – discovery stage
Figure 37: Monoclonal antibody deal royalty rate value distribution, US$million – preclinical stage
Figure 38: Monoclonal antibody deal royalty rate value distribution, US$million – phase I stage
Figure 39: Monoclonal antibody deal royalty rate value distribution, US$million – phase II stage
Figure 40: Monoclonal antibody deal royalty rate value distribution, US$million – phase III stage
Figure 41: Monoclonal antibody deal royalty rate value distribution, US$million – regulatory stage
Figure 42: Monoclonal antibody deal royalty rate value distribution, US$million – marketed stage
Figure 43: Cancer monoclonal antibody deal royalty value – median value by stage of development
Figure 44: Top monoclonal antibody cancer deals by value since 2007
Figure 45: Online partnering resources
Figure 46: Forthcoming partnering events
Figure 47: Deal type definitions
Figure 48: Collaborative R&D agreement for BiTE antibodies against three undisclosed solid tumor targets

Abstract

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes antibody-drug conjugate deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual cancer monoclonal antibody deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer monoclonal antibody dealmaking since 2007, including details of disclosed headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading cancer monoclonal antibody deals since 2007. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of cancer monoclonal antibody partnering deals signed and announced since 2007, and where available, a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific oncology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer monoclonal antibody technologies and products.

Report scope

Cancer Monoclonal Antibody Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

Cancer Monoclonal Antibody Partnering Agreements includes:

Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2007
Analysis of cancer monoclonal antibody deal structure
Access to headline, upfront, milestone and royalty data
Access to over 500 cancer monoclonal antibody deal records
The leading cancer monoclonal antibody deals by value since 2007
Includes antibody-drug conjugates deals and alliances since 2007

In Cancer Monoclonal Antibody Partnering Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific oncology therapy target
Monoclonal antibody type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Monoclonal Antibody Partnering Agreements report provides comprehensive access to available deals and contract documents for over 1,000 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.